Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin αvβ6 Expression

• Published in: The Journal of biological chemistry 2016-04, Vol.291 (18), p.9540-9553
• Main Authors: Tatler, Amanda L., Habgood, Anthony, Porte, Joanne, John, Alison E., Stavrou, Anastasios, Hodge, Emily, Kerama-Likoko, Cheryl, Violette, Shelia M., Weinreb, Paul H., Knox, Alan J., Laurent, Geoffrey, Parfrey, Helen, Wolters, Paul John, Wallace, William, Alberti, Siegfried, Nordheim, Alfred, Jenkins, Gisli
• Format: Article
• Language: English
• Subjects: Animals; Antigens, Neoplasm - biosynthesis; Antigens, Neoplasm - genetics; Cell Line, Transformed; elk1; ets-Domain Protein Elk-1 - genetics; ets-Domain Protein Elk-1 - metabolism; fibrosis; Gene Expression Regulation; gene regulation; Humans; integrin; Integrins - biosynthesis; Integrins - genetics; lung; Mice; Mice, Knockout; Molecular Bases of Disease; pulmonary fibrosis; Pulmonary Fibrosis - chemically induced; Pulmonary Fibrosis - genetics; Pulmonary Fibrosis - metabolism; Pulmonary Fibrosis - pathology; Signal Transduction; Transcription, Genetic; Transforming Growth Factor beta1 - genetics; Transforming Growth Factor beta1 - metabolism
• ISSN: 0021-9258; 1083-351X; 1083-351X
• DOI: 10.1074/jbc.M115.692368

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with high mortality. Active TGFβ1 is considered central to the pathogenesis of IPF. A major mechanism of TGFβ1 activation in the lung involves the epithelially restricted αvβ6 integrin. Expression of the αvβ6 integrin is dramatically increased in IPF. How αvβ6 integrin expression is regulated in the pulmonary epithelium is unknown. Here we identify a region in the β6 subunit gene (ITGB6) promoter acting to markedly repress basal gene transcription, which responds to both the Ets domain-containing protein Elk1 (Elk1) and the glucocorticoid receptor (GR). Both Elk1 and GR can regulate αvβ6 integrin expression in vitro. We demonstrate Elk1 binding to the ITGB6 promoter basally and that manipulation of Elk1 or Elk1 binding alters ITGB6 promoter activity, gene transcription, and αvβ6 integrin expression. Crucially, we find that loss of Elk1 causes enhanced Itgb6 expression and exaggerated lung fibrosis in an in vivo model of fibrosis, whereas the GR agonist dexamethasone inhibits Itgb6 expression. Moreover, Elk1 dysregulation is present in epithelium from patients with IPF. These data reveal a novel role for Elk1 regulating ITGB6 expression and highlight how dysregulation of Elk1 can contribute to human disease.